Business Wire

PA-PPG

15.2.2024 15:01:34 CET | Business Wire | Press release

Share
PPG, PPG Foundation invested more than $17.5 million in communities worldwide in 2023

PPG (NYSE:PPG) and the PPG Foundation today announced that they invested more than $17.5 million worldwide in 2023, an increase of $1.3 million over 2022. The funding supports more than 450 community partners and programs that are focused on advancing education and delivering community sustainability while encouraging PPG employee volunteerism.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215307583/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

PPG and the PPG Foundation invested more than $17.5 million worldwide in 2023 to support over 450 community partners and programs that are focused on advancing education and delivering community sustainability while encouraging PPG employee volunteerism. (Photo: Business Wire)

“In 2023, our purpose to ‘protect and beautify the world’ came to life across all areas of PPG’s community engagement investments. While our employees created colorful classrooms, our funding aimed to advance learning and inspire STEM careers,” said Malesia Dunn, executive director, PPG Foundation and corporate global social responsibility. “With new commitments in environmental sustainability education and workforce development, our priorities and giving centered around creating brighter communities for the future.”

Highlights of the 2023 community engagement commitments include:

  • $10.3 million to build the next generation of science, technology, engineering and mathematics (STEM) leaders.
    • 2023 marked the five-year anniversary of the PPG SCIENCE PAVILION® at the Daniel G. and Carole L. Kamin Science Center (formerly Carnegie Science Center) in Pittsburgh.
    • PPG launched a three-year partnership with the Finnish Science Centre Heureka to help fund Heureka’s new ‘Power of Play’ exhibition and color workshops for young students.
    • PPG teamed up with programs such as Casa Hacker’s ‘Girls in Tech’ in Sumaré, Brazil, for students pursuing advanced STEM studies.
    • Through its partnership with Give2Asia and Live2Give in China, PPG delivered the PPG Scholarship Program at eight universities and the PPG Career Intelligence Class in 15 universities.
    • The PPG Foundation partnered with AdoptAClassroom.org to equip teachers and 10 schools in PPG communities with STEM education tools.
    • In Soborg, Denmark, students visited PPG’s architectural coatings plant as part of Science Day and an ongoing partnership with STEM education group Naturvidenskabernes Hus.
  • Progress in DE&I, sustainability education and workforce development
    • 89% progress made toward the commitment to invest $20 million by 2025 supporting programs for black communities and people of color in the U.S.
    • PPG committed $5 million by 2030 to environmental sustainability education, supporting organizations such as National Environmental Education Foundation (NEEF) in the U.S. and the STEM Learning organization in the U.K.
    • PPG also committed $2 million by 2025 for future skilled worker training through organizations including the Collision Repair Education Foundation (CREF) in the U.S. and donations of PPG MOONWALK® and PPG LINQ™ Pro educational tools to vocational schools in Europe.
  • $6.2 million to community sustainability and disaster and humanitarian relief:
    • PPG and the PPG Foundation contributed to regional organizations supporting local emergency relief and recovery efforts, such as the Red Cross, following natural disasters in Acapulco, Mexico; Emilia-Romagna, Italy; Turkey; Slovenia; and Morocco.
  • 60 COLORFUL COMMUNITIES® projects completed in 2023 in 16 countries:
    • In 2023, PPG’s global Colorful Communities program reached its 500th project milestone. Since 2015, 26,500 PPG employee and community volunteers have positively impacted more than 9.2 million people in 50 countries.
    • In 2023, PPG committed an additional $5 million to the Colorful Communities program through 2030, enabling PPG volunteers to incorporate new activities and elements into projects that focus on environmental sustainability.
    • Throughout June, July and August 2023, the Colorful Communities program completed its second New Paint for a New Start initiative, transforming a total of more than 60 schools into engaging environments for 35,000 students.

Learn more about PPG and the PPG Foundation’s investments in 2023.

PPG’s global community engagement efforts and the PPG Foundation aim to bring color and brightness to PPG communities around the world. We invested more than $17.5 million in 2023, supporting hundreds of organizations across nearly 40 countries. By investing in educational opportunities, we help grow tomorrow’s STEM innovators and skilled workforce in fields related to coatings and manufacturing. Plus, we empower PPG employees to multiply their impact for causes that are important to them by supporting their volunteer efforts and charitable giving. Learn more here.

PPG: WE PROTECT AND BEAUTIFY THE WORLD®

At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for more than 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $18.2 billion in 2023. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.

PPG LINQ is a trademark and Colorful Communities, MoonWalk, the PPG Logo and We protect and beautify the world are registered trademarks of PPG Industries Ohio, Inc.

CATEGORY Community Affairs

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240215307583/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye